Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04176627
Other study ID # SIH_122_Fluid-PLUS
Secondary ID
Status Completed
Phase
First received
Last updated
Start date December 2, 2019
Est. completion date June 30, 2020

Study information

Verified date November 2019
Source Satellite Healthcare
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

- As studied previously, lung congestion is very prevalent however usually asymptomatic in dialysis patients. Fluid overload is associated with hospitalizations, worse cardiovascular outcomes and mortality in PD patients.

- The clinical exam is the only tool used currently to monitor volume status of PD patients, and has been found to have poor sensitivity and specificity for lung congestion compared to lung ultrasound. In current practice, patients are seen and examined monthly at their home dialysis units by the nurses. The nephrologist separately examines the patient monthly, possibly days to weeks after the nurse visit, and potentially only quarterly with the use of telehealth visits.

- Lung ultrasound is a relatively simple and cheap tool to assess for lung congestion, with little inter-operator variability and good reproducibility.

- There are limited studies of lung ultrasound in peritoneal dialysis, and none in the United States. Lung ultrasound may be useful as an objective measure of lung congestion in patients without signs or symptoms of fluid overload.

Aims of this study

- This study aims to determine the prevalence of subclinical fluid overload in peritoneal dialysis patients.

- The investigators aim to determine the added benefit of lung ultrasound to standard clinical practice of fluid management in PD patients.

- The investigators aim to assess the association of patient characteristics with lung congestion.

- The investigators also aim to assess the agreement between nurse physical exam and lung ultrasound for fluid overload.


Description:

Study Design:

- Cross-sectional study, inviting PD patients at 10 Northern CA home dialysis units to participate. One-time ultrasound done during monthly nurse visit between December 2019 and March 2020. All patients present for their monthly visit at participating home dialysis units on days in which ultrasound available will be eligible, unless they had already completed an ultrasound for the study.

- Eligible patients approached for informed consent

- Ultrasound method: 28 areas of the anterior and lateral thorax examined for B lines, need at least 3 B lines in each field to be counted- recorded for future validation

- Training: lung ultrasound training modules accredited by American College of Emergency Physicians, in addition to dedicated rotation of ultrasound training during internal medicine residency.

- Separate nurse clinical evaluation- yes or no, nurse blinded from ultrasound results

- Patient characteristics obtained from dialysis EHR and form 2728: Age, gender (male sex %), race, ethnicity, case of ESRD, dialysis vintage (mo), PD modality, BMI, DM (%), SBP, DBP, albumin , # of antihypertensives, use of diuretic, use of icodextrin, PD Rx, 24 hour urine volume, lung disease (%), heart failure (%)

- Lung ultrasound info documented in EHR along with nurse evaluation. If moderate-severe lung congestion on ultrasound, nephrologist notified in person, by phone or fax.

- Prescription changes from nephrologist (diuretic adjustment, dextrose concentration change, addition of icodextrin, or none) within 2 weeks tracked in EHR and/or in person with dialysis nurse

- Sample size calculation- assuming 30% subclinical fluid overload prevalence, 95% confidence interval of prevalence of subclinical fluid overload with 10% margin of error-> 81 patients


Recruitment information / eligibility

Status Completed
Enrollment 44
Est. completion date June 30, 2020
Est. primary completion date April 1, 2020
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Peritoneal dialysis patients seen at participating Wellbound clinics in Northern California, present for monthly visit on days in which lung ultrasound available

Exclusion Criteria:

- Age <18, on peritoneal dialysis <3 mo, symptomatic lung congestion (reporting new or worsening shortness of breath over the past 4 weeks on enrollment), patient or nephrologist unwilling to participate in study

Study Design


Intervention

Device:
Lung ultrasound
One-time lung ultrasound study completed on peritoneal dialysis patients at monthly clinic visit

Locations

Country Name City State
United States WellBound Daly City Daly City California
United States Satellite WellBound Emeryville Emeryville California
United States Satellite WellBound Fremont Fremont California
United States Satellite WellBound Milpitas Milpitas California
United States WellBound Modesto Modesto California
United States WellBound North Modesto Modesto California
United States Satellite WellBound Mountain View Mountain View California
United States WellBound Sacramento Sacramento California
United States WellBound San Francisco San Francisco California
United States Satellite WellBound San Jose San Jose California
United States WellBound San Leandro San Leandro California
United States Satellite WellBound San Mateo San Mateo California
United States Wellbound Santa Cruz Santa Cruz California
United States WellBound Santa Rosa Santa Rosa California
United States WellBound Stockton Stockton California
United States WellBound Vallejo Vallejo California

Sponsors (1)

Lead Sponsor Collaborator
Satellite Healthcare

Country where clinical trial is conducted

United States, 

References & Publications (4)

Gargani L, Sicari R, Raciti M, Serasini L, Passera M, Torino C, Letachowicz K, Ekart R, Fliser D, Covic A, Balafa O, Stavroulopoulos A, Massy ZA, Fiaccadori E, Caiazza A, Bachelet T, Slotki I, Shavit L, Martinez-Castelao A, Coudert-Krier MJ, Rossignol P, — View Citation

Panuccio V, Enia G, Tripepi R, Torino C, Garozzo M, Battaglia GG, Marcantoni C, Infantone L, Giordano G, De Giorgi ML, Lupia M, Bruzzese V, Zoccali C. Chest ultrasound and hidden lung congestion in peritoneal dialysis patients. Nephrol Dial Transplant. 20 — View Citation

Torino C, Gargani L, Sicari R, Letachowicz K, Ekart R, Fliser D, Covic A, Siamopoulos K, Stavroulopoulos A, Massy ZA, Fiaccadori E, Caiazza A, Bachelet T, Slotki I, Martinez-Castelao A, Coudert-Krier MJ, Rossignol P, Gueler F, Hannedouche T, Panichi V, Wi — View Citation

Zoccali C, Torino C, Tripepi R, Tripepi G, D'Arrigo G, Postorino M, Gargani L, Sicari R, Picano E, Mallamaci F; Lung US in CKD Working Group. Pulmonary congestion predicts cardiac events and mortality in ESRD. J Am Soc Nephrol. 2013 Mar;24(4):639-46. doi: — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Prevalence of subclinical fluid overload in peritoneal dialysis patients percentage of patients with moderate-severe lung congestion on ultrasound and nurse physical exam without fluid overload single monthly nurse visit
Secondary Added benefit of lung ultrasound to standard clinical practice of fluid management in PD patients percentage of patients with subclinical fluid overload who have a change in PD prescription or diuretics single monthly nurse visit
Secondary Association of patient characteristics with lung congestion Odds ratios for lung congestion from subgroup analyses and logistic regression single monthly nurse visit
Secondary Agreement between nurse physical exam and lung ultrasound for fluid overload kappa coefficient between lung ultrasound and nurse exam for fluid overload single monthly nurse visit
See also
  Status Clinical Trial Phase
Not yet recruiting NCT04034628 - Improving the Outcomes of Peritoneal Dialysis (PD) Catheter Insertion
Completed NCT03569410 - The Effect of Natural Protein vs. Protein Supplements on Peritoneal Dialysis Patients N/A
Completed NCT04302649 - Dialysate Temperature in Peritoneal Dialysis Phase 4
Enrolling by invitation NCT05250752 - Reduction of Peritoneal Glucose Uptake With Use of SGLT2 in Humans Undergoing Peritoneal Dialysis Treatment Phase 2
Recruiting NCT03563898 - Feasibility and Safety in the Management of Fluid Overload in Peritoneal Dialysis Patients Through Sweat Stimulation With the Use of Portable Sauna Bath, Pilot Study N/A
Recruiting NCT03046511 - Peritonitis Prevention After Insertion of Peritoneal Dialysis Catheter. Phase 3
Not yet recruiting NCT05224466 - Characteristics and Clinical Outcomes of Peritoneal Dialysis Patients
Completed NCT03458819 - EMT in Peritoneal Dialysis Patients
Recruiting NCT06398977 - Dapagliflozin Delays the Loss of Renal Function in Peritoneal Dialysis Patients N/A
Not yet recruiting NCT06045858 - SAFETY AND EFFICACY OF APIXABAN VERSUS WARFARIN IN PERITONEAL DIALYSIS PATIENTS WITH NON VALVULAR ATRIAL FIBRILLATION: A PROSPECTIVE, RANDOMISED, OPEN-LABEL, BLINDED END-POINT TRIAL (APIDP2) Phase 3
Active, not recruiting NCT04034966 - Utility of Telemedicine in the Follow-Up of Patients in Peritoneal Dialysis N/A
Completed NCT04923295 - The Effect of Dapagliflozin on Ultrafiltration Among Peritoneal Dialysis Patients N/A
Not yet recruiting NCT05715814 - meChANisms and sAfety of SGLT2 Inhibition in peRitoneal dialYsis Phase 3
Recruiting NCT03148002 - Peritoneal Dialysis Pilot Study: Evaluating Polyethylene Glycol (PEG) for Constipation Phase 4
Recruiting NCT04572724 - The Effect of Sacubitril/Valsartan on Cardiovascular Events in Dialysis Patients and Efficacy Prediction of Baseline LVEF Value Phase 4
Completed NCT05797181 - The Effect Of Medical Nutritional Therapy On Patients With Sarcopenic Obesity Receiving Peritoneal Dialysis Treatment N/A
Recruiting NCT01893710 - International (Pediatric) Peritoneal Biobank
Completed NCT03382444 - The Kidney and The Brain Study - Assessment of Cognitive Impairment in Advanced CKD
Completed NCT04046263 - Effect of Velphoro on Serum Phosphate and Albumin in Peritoneal Dialysis Patients Phase 4
Completed NCT03759002 - Association of Mean Platelet Volume and Cardiovascular Disease in Children With End Stage Renal Disease.